These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29899212)

  • 41. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers.
    Sahre M; Sabarinath S; Grant M; Seubert C; Deanda C; Prokocimer P; Derendorf H
    Int J Antimicrob Agents; 2012 Jul; 40(1):51-4. PubMed ID: 22584101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
    Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
    J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.
    Hendershot PE; Antal EJ; Welshman IR; Batts DH; Hopkins NK
    J Clin Pharmacol; 2001 May; 41(5):563-72. PubMed ID: 11361053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.
    Darwish M; Hellriegel ET; Xie F
    Clin Drug Investig; 2008; 28(12):793-801. PubMed ID: 18991473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.
    Ferrández O; Urbina O; Grau S
    Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.
    Durkin MJ; Corey GR
    Ther Clin Risk Manag; 2015; 11():857-62. PubMed ID: 26045667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
    Robbins B; Chang CT; Cramer JA; Garreffa S; Hafkin B; Hunt TL; Meligeni J
    Clin Pharmacol Ther; 1996 Mar; 59(3):275-83. PubMed ID: 8653990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children.
    Gelotte CK; Prior MJ; Pendley C; Zimmerman B; Lavins BJ
    Clin Pediatr (Phila); 2010 Jul; 49(7):678-85. PubMed ID: 20356918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
    Rubino CM; Bhavnani SM; Loutit JS; Morgan EE; White D; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tedizolid for treatment of acute bacterial skin and skin structure infections.
    Hui Y; Xiaoju L
    Expert Rev Anti Infect Ther; 2015; 13(9):1051-60. PubMed ID: 26211946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
    Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
    J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.